Legacy CG’s Gilead Sciences GILD Stock Holding History

Legacy CG’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-175	Closed	-$11K	–	77
2022 Q2	$11K	Buy	+175	New	+$10.8K	0.01%	98

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legacy CG's GILD Position: Q3 2022 in Review

Legacy CG sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 175 shares — an estimated $11K sold.

Legacy CG first reported a position in GILD in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

Legacy CG reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
Legacy CG sold 175 Gilead Sciences shares in Q3 2022, an estimated $11K.
Legacy CG first reported a position in Gilead Sciences in Q2 2022 and held it in 1 quarter.
Legacy CG's Gilead Sciences position peaked at $11K in Q2 2022.
1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Legacy CG's 13F filing for Q3 2022, filed 4 Nov 2022.